← Leaderboards
Kenneth Chan
Ohio State University
$594,246
Attributed
$594,246
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $536K · FY2009–11$1M$750K$500K$250K$0
'09
'10
'11
Funding mix
By agency
NIH$594,246 · 2
By mechanism
N01$594,246 · 1
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Krista Marie Dubray La Perle$1,632,491
- Mark R Parthun$8,798,119
- Michael A Caligiuri$65,062,344
- Jill A Rafael-Fortney$9,863,077
- David P Carbone$20,647,321
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectApoptosisPharmacokineticsHuman Therapy EvaluationDna ReplicationClinical ResearchHead /Neck NeoplasmNeoplasm /Cancer ChemotherapyDna RepairAntineoplasticsArea Under CurveBody FluidsCancer TherapyCanis FamiliarisBiological ModelsAnimal TissueBiological AvailabilityContractorContinuous InfusionBiologicalContractsDesignComputing MethodologiesClinical Trials
Grant awards (5)
Preclinical Pharmacological Studies$58,200
N01 · FY2011 · CA · contact PI
Preclinical Pharmacological Studies$536,046
N01 · FY2009 · CA · contact PI
PHASE II STUDY OF OXALIPLATIN IN PATIENTS WITH ADVANCED CARCINOMA OF THE HEAD$0
M01 · FY2001 · RR
PHASE II STUDY OF OXALIPLATIN IN PATIENTS WITH ADVANCED CARCINOMA OF THE HEAD$0
M01 · FY2000 · RR
PHASE II STUDY OF OXALIPLATIN IN PATIENTS WITH ADVANCED CARCINOMA OF THE HEAD$0
M01 · FY2000 · RR